




Instance: composition-en-67d662579a878d3df2de1273192e0a02
InstanceOf: CompositionUvEpi
Title: "Composition for briviact Package Leaflet"
Description:  "Composition for briviact Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp67d662579a878d3df2de1273192e0a02)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - briviact"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Briviact is and what it is used for  </li>
<li>What you need to know before you take Briviact </li>
<li>How to take Briviact </li>
<li>Possible side effects  </li>
<li>How to store Briviact  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What briviact is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What briviact is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Briviact is 
Briviact contains the active substance brivaracetam. It belongs to a group of medicines called 
 anti-epileptics . These medicines are used to treat epilepsy. </p>
<p>What Briviact is used for 
* Briviact is used in adults, adolescents and children from 2 years of age. 
* It is used to treat a type of epilepsy that has partial seizures with or without a secondary 
generalisation.<br />
<em> Partial seizures are fits that start by only affecting one side of the brain. These partial seizures 
can spread and extend to larger areas on both sides of the brain   this is called a  secondary 
generalisation .<br />
</em> You have been given this medicine to lower the number of fits (seizures) you have.<br />
* Briviact is used together with other medicines for epilepsy. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Briviact if:</p>
<ul>
<li>you are allergic to brivaracetam, other similar chemical compounds as levetiracetam or 
piracetam or any of the other ingredients of this medicine (listed in section 6). If you are not 
sure, talk to your doctor or pharmacist before taking Briviact.  </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Briviact if:</p>
<ul>
<li>You have thoughts of harming or killing yourself. A small number of people being treated with 
anti-epileptic medicines such as Briviact have had thoughts of harming or killing themselves. If 
you have any of these thoughts at any time, contact your doctor immediately. </li>
<li>You have liver problems - your doctor may need to adjust your dose. </li>
</ul>
<p>Children<br />
Briviact is not recommended for use in children under 2 years of age. </p>
<p>Other medicines and Briviact 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, tell your doctor if you are taking any of the following medicines   this is because your 
doctor may need to adjust your Briviact dose:</p>
<ul>
<li>Rifampicin - a medicine used to treat bacterial infections. </li>
<li>St John s wort (also known as Hypericum perforatum) - a herbal medicine used to treat 
depression and anxiety as well as other conditions. </li>
</ul>
<p>Briviact with alcohol 
- Combining this medicine with alcohol is not recommended.<br />
- If you drink alcohol while taking Briviact the negative effects of alcohol may be increased.  </p>
<p>Pregnancy and breast-feeding 
Fertile women should discuss the use of contraceptives with the doctor. </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine. </p>
<p>It is not recommended to take Briviact if you are pregnant, as the effects of Briviact on pregnancy and 
the unborn baby are not known. 
It is not recommended to breast-feed your baby while taking Briviact, as Briviact passes into breast 
milk. </p>
<p>Do not stop treatment without talking to your doctor first. Stopping treatment could increase your 
seizures and harm your baby. </p>
<p>Driving and using machines 
- You may feel sleepy, dizzy or tired while taking Briviact.<br />
- These effects are more likely at the start of the treatment or after a dose increase. 
- Do not drive, cycle or use any tools or machines until you know how the medicine affects you. </p>
<p>Briviact contains lactose and sodium 
Briviact film-coated tablets contain:</p>
<ul>
<li>lactose (a type of sugar) - If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicine. </li>
<li>sodium   This medecine contains less than 1 mmol sodium (23mg) per tablet, that is to say 
essentially  sodium free . </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. Other form(s) of this medicine may be more suitable for certain patients e.g. 
children (if tablets can not be swallowed in whole, for example); ask your doctor or pharmacist. </p>
<p>You will take Briviact together with other medicines for epilepsy. </p>
<p>How much to take 
Your doctor will work out the right daily dose for you.Take the daily dose in two equal divided doses, 
approximately 12 hours apart. </p>
<p>Adolescents and children weighing 50 kg or more, and adults 
- The recommended dose is from 25 mg to 100 mg taken twice a day . Your doctor may then 
decide to adjust your dose to find the best dose for you.   </p>
<p>Adolescents and children weighing from 20 kg to less than 50 kg<br />
- The recommended dose is from 0.5 mg to 2 mg for each kg of bodyweight, taken twice a day. 
Your doctor may then decide to adjust your dose to find the best dose for you. </p>
<p>Children weighing from 10 kg to less than 20 kg<br />
- The recommended dose is from 0.5 mg to 2.5 mg for each kg of bodyweight, taken twice a day. 
Your child s doctor may then decide to adjust your child s dose to find the best dose for your 
child. </p>
<p>People with liver problems 
If you have problems with your liver:</p>
<ul>
<li>As an adolescent or child weighing 50 kg or more, or as an adult, the maximum dose you will 
take is 75 mg twice a day.  </li>
<li>As an adolescent or child weighing from 20 kg to less than 50 kg, the maximum dose you will 
take is 1.5 mg for each kg of bodyweight twice a day. </li>
<li>As a child weighing from 10 kg to less than 20 kg, the maximum dose your child will take is 
2 mg for each kg of bodyweight twice a day. </li>
</ul>
<p>How to take Briviact tablets 
- Swallow the tablets whole with a glass of liquid.<br />
- The medicine may be taken with or without food. </p>
<p>How long to take Briviact for 
Briviact is a long term treatment   keep taking Briviact until your doctor tells you to stop.  </p>
<p>If you take more Briviact than you should 
If you have taken more Briviact than you should, talk to your doctor. You may feel dizzy and sleepy. 
You may also have any of the following symptoms: feeling sick, a feeling of  spinning , problems of 
keeping your balance, anxiety, feeling very tired, irritability, being aggressive, not being able to sleep, 
depression, thoughts or attempts of harming or killing yourself. </p>
<p>If you forget to take Briviact 
- If you miss a dose take it as soon as you remember.<br />
- Then take your next dose at the time you would normally take it.<br />
- Do not take a double dose to make up for a forgotten dose. 
- If you are not sure what to do, ask your doctor or pharmacist. </p>
<p>If you stop taking Briviact 
- Do not stop taking this medicine unless your doctor tells you to. This is because stopping 
treatment could increase the number of fits you have. 
- If your doctor asks you to stop taking this medicine they will lower your dose gradually. This 
helps to stop your fits coming back or getting worse  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common: may affect more than 1 in 10 people 
- feeling sleepy or dizzy </p>
<p>Common: may affect up to 1 in 10 people 
- flu 
- feeling very tired (fatigue) 
- convulsion, a feeling of  spinning  (vertigo) 
- feeling and being sick, constipation 
- depression, anxiety, not being able to sleep (insomnia), irritability 
- infections of the nose and throat (such as the  common cold ), cough 
- decreased appetite  </p>
<p>Uncommon: may affect up to 1 in 100 people 
- allergic reactions 
- abnormal thinking and/or loss of touch with reality (psychotic disorder), being aggressive, 
nervous excitement (agitation)<br />
- thoughts or attempts of harming or killing yourself: tell your doctor straight away 
- a decrease in white blood cells (called  neutropenia ) - shown in blood tests  </p>
<p>Additional side effects in children  </p>
<p>Common: may affect up to 1 in 10 people 
- restlessness and hyperactivity (psychomotor hyperactivity)  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not use this medicine after the expiry date which is stated on the carton and blister after 
EXP. The expiry date refers to the last day of that month. </li>
<li>This medicinal product does not require any special storage conditions. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how 
to throw away medicines you no longer use. These measures will help protect the environment. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Briviact contains<br />
The active substance is brivaracetam. 
Each film-coated tablet contains 10 mg, 25 mg, 50 mg, 75 mg, or 100 mg brivaracetam. </p>
<p>The other ingredients are: 
Core 
Croscarmellose sodium, lactose monohydrate, betadex, lactose anhydrous, magnesium stearate  </p>
<p>Coating 
- 10 mg film-coated tablets: poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc. 
- 25 mg film-coated tablets: poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron 
oxide yellow (E172), iron oxide black (E172). 
- 50 mg film-coated tablets: poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron 
oxide yellow (E172), iron oxide red (E172). 
- 75 mg film-coated tablets: poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron 
oxide yellow (E172), iron oxide red (E172), iron oxide black (E172). </p>
<ul>
<li>100 mg film-coated tablets: poly(vinyl alcohol), titanium dioxide (E171), macrogol (3350), talc, iron 
oxide yellow (E172), iron oxide black (E172). </li>
</ul>
<p>What Briviact looks like and contents of the pack 
Briviact 10 mg are white to off-white, round, film-coated tablets of 6.5 mm in diameter and debossed 
with  u10  on one side. 
Briviact 25 mg are grey, oval, film-coated tablets of 8.9 mm x 5.0 mm and debossed with  u25  on one 
side. 
Briviact 50 mg are yellow, oval, film-coated tablets of 11.7 mm x 6.6 mm and debossed with  u50  on 
one side. 
Briviact 75 mg are purple, oval, film-coated tablets of 13.0 mm x 7.3 mm and debossed with  u75  on 
one side.<br />
Briviact 100 mg are green-grey, oval, film-coated tablets of 14.5 mm x 8.1 mm and debossed with 
 u100  on one side. </p>
<p>Briviact tablets are packaged in blister packs supplied in cardboard boxes containing either 14, 56, 
14 x 1 or 100 x 1 film-coated tablets or in multipacks containing 168 (3 packs of 56) film-coated 
tablets. 
All packs are available in PVC/PCTFE - Aluminium blisters. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
UCB Pharma S.A., All e de la Recherche 60, B-1070 Bruxelles, Belgium.  </p>
<p>Manufacturer 
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l Alleud, Belgium. 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
UCB Pharma SA/NV 
T l/Tel: + 32 / (0)2 559 92 Lietuva 
UCB Pharma Oy Finland 
Tel: + 358 9 2514 4221 (Suomija) </p>
<p>Te .: + 359 (0) 2 962 30 Luxembourg/Luxemburg 
UCB Pharma SA/NV 
T l/Tel: + 32 / (0)2 559 92 00 (Belgique/Belgien) </p>
<p>esk  republika 
UCB s.r.o. 
Tel: + 420 221 773 Magyarorsz g 
UCB Magyarorsz g Kft. 
Tel.: + 36-(1) 391 0Danmark 
UCB Nordic A/S 
Tlf: + 45 / 32 46 24 Malta 
Pharmasud Ltd. 
Tel: + 356 / 21 37 64 Deutschland 
UCB Pharma GmbH 
Tel: + 49 /(0) 2173 48 4Nederland 
UCB Pharma B.V. 
Tel.: + 31 / (0)76-573 11 Eesti 
UCB Pharma Oy Finland<br />
Tel: + 358 9 2514 4221 (Soome) </p>
<p>Norge 
UCB Nordic A/S 
Tlf: + 47 / 67 16 5<br />
UCB  . .<br />
 : + 30 / 2109974 sterreich 
UCB Pharma GmbH 
Tel: + 43-(0)1 291 80 Espa a 
UCB Pharma, S.A. 
Tel: + 34 / 91 570 34 Polska 
UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. 
Tel: + 48 22 696 99 France 
UCB Pharma S.A. 
T l: + 33 / (0)1 47 29 44 Portugal 
UCB Pharma (Produtos Farmac uticos), Lda 
Tel: + 351 / 21 302 5Hrvatska 
Medis Adria d.o.o. 
Tel: +385 (0) 1 230 34 Rom nia 
UCB Pharma Romania S.R.L. 
Tel: + 40 21 300 29 Ireland 
UCB (Pharma) Ireland Ltd. 
Tel: + 353 / (0)1-46 37 Slovenija 
Medis, d.o.o. 
Tel: + 386 1 589 69  sland 
Vistor hf. 
Simi: + 354 535 7Slovensk  republika 
UCB s.r.o., organiza n  zlo ka 
Tel: + 421 (0) 2 5920 2Italia 
UCB Pharma S.p.A. 
Tel: + 39 / 02 300 Suomi/Finland 
UCB Pharma Oy Finland 
Puh/Tel: + 358 9 2514 4<br />
Lifepharma (Z.A.M.) Ltd 
 : + 357 22 05 63 Sverige 
UCB Nordic A/S 
Tel: + 46 / (0) 40 29 49 Latvija 
UCB Pharma Oy Finland 
Tel: + 358 9 2514 4221 (Somija) </p>
<p>United Kingdom (Northern Ireland) 
UCB (Pharma) Ireland Ltd. 
Tel: + 353 / (0)1-46 37 This leaflet was last revised in {month YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-67d662579a878d3df2de1273192e0a02
InstanceOf: CompositionUvEpi
Title: "Composition for briviact Package Leaflet"
Description:  "Composition for briviact Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp67d662579a878d3df2de1273192e0a02)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - briviact"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal De vide, før De begynder at tage Briviact 
3. Sådan skal De tage Briviact 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What briviact is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What briviact is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Briviact indeholder det aktive stof brivaracetam. Det tilhører en gruppe af lægemidler, som kaldes 
"antiepileptika". Disse lægemidler anvendes til behandling af epilepsi. </p>
<p>Anvendelse 
- Briviact anvendes hos voksne, unge og børn på 2 år og derover. 
- Det bruges til behandling af en bestemt type epilepsi med "partielle anfald med eller uden 
sekundær generalisering."<br />
- Partielle anfald er kramper, som til at begynde med kun påvirker en side af hjernen. Disse 
partielle anfald kan sprede og udvide sig til større områder i begge sider af hjernen - dette 
kaldes en "sekundær generalisering".<br />
- De har fået dette lægemiddel for at nedbringe antallet af kramper (anfald). Briviact anvendes 
sammen med andre lægemidler mod epilepsi. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Briviact, hvis:</p>
<ul>
<li>De er allergisk over for brivaracetam, andre lignende kemiske stoffer, såsom levetiracetam eller 
piracetam, eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6). Hvis De er 
usikker, skal De tale med lægen eller apotekspersonalet, før De tager Briviact. </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Briviact, hvis:</p>
<ul>
<li>De har tanker om at skade Dem selv eller har selvmordstanker. En lille del af de personer, der 
bliver behandlet med epilepsimedicin, som f.eks. Briviact, har haft tanker om at gøre skade på 
sig selv eller selvmordstanker. Hvis De på noget tidspunkt får sådanne tanker, skal De kontakte 
lægen omgående. </li>
<li>De har leverproblemer, det kan være nødvendigt for lægen at justere dosis. </li>
</ul>
<p>Børn<br />
Briviact er ikke beregnet til anvendelse hos børn under 2 år. </p>
<p>Brug af anden medicin sammen med Briviact 
Fortæl altid lægen eller apotekspersonalet, hvis De tager anden medicin eller har gjort det for nylig. </p>
<p>Det er især vigtigt at fortælle lægen, hvis De tager et af følgende lægemidler, da det kan være 
nødvendigt, at lægen justerer dosis af Briviact:</p>
<ul>
<li>Rifampicin - et lægemiddel, som anvendes til behandling af infektioner, som skyldes bakterier. </li>
<li>Prikbladet perikon (også kendt som Hypericum perforatum), som er et naturlægemiddel, som 
anvendes til behandling af depression og angst samt andre tilstande. </li>
</ul>
<p>Brug af Briviact sammen med alkohol 
- Det er ikke tilrådeligt at kombinere dette lægemiddel med alkohol. 
- Hvis De drikker alkohol under behandlingen med Briviact, kan de negative virkninger af 
alkohol øges.  </p>
<p>Graviditet og amning 
Kvinder, som er i stand til at få børn, skal drøfte brugen af prævention med lægen. </p>
<p>Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Det anbefales ikke at tage Briviact, hvis De er gravid, da virkningen af Briviact på graviditeten og det 
ufødte barn ikke er kendt. 
Det anbefales ikke at amme Deres barn, mens De tager Briviact, da Briviact passerer over i 
modermælken. </p>
<p>Stop ikke behandlingen uden at tale med lægen først. Ophør af behandling kan øge antallet af anfald 
og skade Deres barn. </p>
<p>Trafik- og arbejdssikkerhed 
- De kan føle Dem søvnig, svimmel eller træt under behandlingen med Briviact. 
- Disse symptomer er mest almindelige i starten af behandlingen og efter øgning af dosis. 
- De må ikke føre motorkøretøj, cykle eller bruge værktøj eller maskiner, før De ved, hvordan 
dette lægemiddel påvirker Dem. </p>
<p>Briviact indeholder lactose og natrium 
Briviact filmovertrukne tabletter indeholder:</p>
<ul>
<li>lactose (en sukkerart). Kontakt lægen, før De tager dette lægemiddel, hvis lægen har fortalt 
Dem, at De ikke tåler visse sukkerarter. </li>
<li>natrium. Dette lægemiddel indeholder mindre end1 mmol (23 mg) natrium pr. tablet, dvs. det er 
i det væsentlige natriumfrit. </li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. Andre former af dette lægemiddel kan være bedre egnet til visse patienter, f.eks. 
børn (f.eks. hvis tabletter ikke kan synkes hele). Spørg lægen eller apotekspersonalet til råds. </p>
<p>De vil tage Briviact sammen med andre lægemidler til behandling af epilepsi. </p>
<p>Hvor meget skal De tage 
Lægen vil bestemme den korrekte dosis for Dem. Tag den daglige dosis fordelt på to lige store doser 
med ca. 12 timers mellemrum. </p>
<p>Unge og børn, som vejer 50 kg eller derover, og voksne 
- Den anbefalede dosis er mellem 25 mg og 100 mg, som tages to gange dagligt. Lægen kan 
derefter vælge at justere dosis for at finde den bedste dosis for Dem. </p>
<p>Unge og børn, som vejer fra 20 kg til under 50 kg 
- Den anbefalede dosis er mellem 0,5 mg og 2 mg per hvert kg kropsvægt, som tages to gange 
dagligt. Lægen kan derefter vælge at justere dosis for at finde den bedste dosis for Dem. 
-<br />
Børn, som vejer fra 10 kg til under 20 kg 
- Den anbefalede dosis er mellem 0,5 mg og 2,5 mg per hvert kg kropsvægt, som tages to gange 
dagligt. Deres barns læge kan derefter vælge at justere dosis for at finde den bedste dosis for 
Deres barn. </p>
<p>Personer med leverproblemer 
Hvis De har leverproblemer:</p>
<ul>
<li>Som ung eller barn, der vejer 50 kg eller derover, eller som voksen, er den maksimale dosis 
75 mg to gange dagligt. </li>
<li>Som ung eller barn, der vejer fra 20 kg til under 50 kg, er den maksimale dosis 1,5 mg per kg 
kropsvægt to gange dagligt. </li>
<li>Som barn, der vejer fra 10 kg til under 20 kg, er den maksimale dosis 2 mg per kg kropsvægt to 
gange dagligt. </li>
</ul>
<p>Sådan skal De tage Briviact tabletter 
- Tabletterne synkes hele sammen med et glas væske. 
- Lægemidlet kan tages med eller uden mad. </p>
<p>Hvor længe skal De tage Briviact 
Briviact er til langtidsbehandling - fortsæt med at tage Briviact, indtil lægen siger, at De skal stoppe 
behandlingen. </p>
<p>Hvis De har taget for meget Briviact 
Kontakt lægen, hvis De har taget mere Briviact, end De skulle. De kan føle Dem svimmel og søvnig. 
De kan også få et eller flere af følgende symptomer: kvalme, en følelse af at "snurre rundt", problemer 
med at holde balancen, angst, voldsom træthedsfølelse, irritabilitet, aggressivitet, søvnløshed, 
depression, tanker om eller forsøg på selvskade eller selvmord. </p>
<p>Hvis De har glemt at tage Briviact 
- Hvis De har glemt at tage en dosis, skal De tage den, så snart De kommer i tanker om det. 
- Tag derefter den næste dosis til sædvanlig tid. 
- De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
- Kontakt lægen eller apotekspersonalet, hvis De er usikker på, hvad De skal gøre. </p>
<p>Hvis De holder op med at tage Briviact 
- Stop ikke med at tage dette lægemiddel medmindre lægen siger, at De skal. Dette skyldes, at 
stop i behandling kan medføre en stigning i antallet af kramper. 
- Hvis lægen beslutter, at behandlingen med dette lægemiddel skal stoppe, vil han/hun gradvist 
nedtrappe dosis. Dette forhindrer, at kramperne vender tilbage eller forværres. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelig: kan forekomme hos flere end 1 ud af 10 personer 
- søvnighed eller svimmelhed </p>
<p>Almindelig: kan forekomme hos op til 1 ud af 10 personer 
- influenza 
- voldsom træthedsfølelse<br />
- kramper, en følelse af at snurre rundt (vertigo) 
- kvalme eller opkastning, forstoppelse 
- depression, angst, søvnløshed (insomni), irritabilitet 
- infektioner i næsen eller halsen (såsom en "almindelig forkølelse"), hoste 
- nedsat appetit </p>
<p>Ikke almindelig: kan forekomme hos op til 1 ud af 100 personer 
- allergiske reaktioner 
- unormal tankegang og/eller manglende realitetssans (psykiske forstyrrelser), aggressivitet, 
nervøs ophidselse (agitation) 
- tanker om eller forsøg på selvmord eller selvskade: fortæl det straks til lægen 
- nedsat antal hvide blodlegemer i blodet (kaldet "neutropi") - ses i blodprøver </p>
<p>Yderligere bivirkninger hos børn  </p>
<p>Almindelig: kan påvirke op til 1 ud af 10 personer 
- rastløshed og hyperaktivitet (psykomotorisk hyperaktivitet) </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store briviact"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store briviact"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Opbevar dette lægemiddel utilgængeligt for børn. </li>
<li>Tag ikke dette lægemiddel efter den udløbsdato, der står på kartonen eller blisteren efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </li>
<li>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </li>
<li>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Briviact indeholder: 
Aktivt stof: brivaracetam. 
Hver filmovertrukken tablet indeholder 10 mg, 25 mg, 50 mg, 75 mg eller 100 mg brivaracetam. </p>
<p>Øvrige indholdsstoffer:<br />
Kerne 
Croscarmellosenatrium; lactosemonohydrat; betadex; lactose, vandfri; magnesiumstearat. </p>
<p>Overtræk 
- 10 mg filmovertrukne tabletter: polyvinylalkohol; titandioxid (E 171); macrogol (3350); talcum. 
- 25 mg filmovertrukne tabletter: polyvinylalkohol; titandioxid (E 171); macrogol (3350); talcum; 
gul jernoxid (E 172); sort jernoxid (E 172). 
- 50 mg filmovertrukne tabletter: polyvinylalkohol; titandioxid (E 171); macrogol (3350); talcum; 
gul jernoxid (E 172); rød jernoxid (E 172). 
- 75 mg filmovertrukne tabletter: polyvinylalkohol; titandioxid (E 171); macrogol (3350); talcum; 
gul jernoxid (E 172); rød jernoxid (E 172); sort jernoxid (E 172). 
- 100 mg filmovertrukne tabletter: polyvinylalkohol; titandioxid (E 171); macrogol (3350); 
talcum; gul jernoxid (E 172); sort jernoxid (E 172). </p>
<p>Udseende og pakningsstørrelser 
Briviact 10 mg er hvide til gråhvide, runde, filmovertrukne tabletter med en diameter på 6,5 mm og er 
præget med "u10" på den ene side. 
Briviact 25 mg er grå, ovale, filmovertrukne tabletter, der måler 8,9 mm x 5,0 mm og er præget med 
"u25" på den ene side. 
Briviact 50 mg er gule, ovale, filmovertrukne tabletter, der måler 11,7 mm x 6,6 mm og er præget med 
"u50" på den ene side. 
Briviact 75 mg er lilla, ovale, filmovertrukne tabletter, der måler 13,0 mm x 7,3 mm og er præget med 
"u75" på den ene side. 
Briviact 100 mg er grøn-grå, ovale, filmovertrukne tabletter, der måler 14,5 mm x 8,1 mm og er 
præget med "u100" på den ene side. </p>
<p>Briviact tabletter er pakket i blisterpakninger, som leveres i æsker indeholdende enten 14, 56, 14 x 1 
eller 100 x 1 filmovertrukne tabletter eller i multipakninger indeholdende 168 (3 pakninger a 56) 
filmovertrukne tabletter. 
Alle pakninger fås i PVC/PCTFE - Aluminium blister. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen<br />
UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgien </p>
<p>Fremstiller 
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgien </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
UCB Pharma SA/NV 
Tél/Tel: + 32 / (0)2 559 92<br />
Lietuva 
UCB Pharma Oy Finland 
Tel: + 358 9 2514 4221 (Suomija) </p>
<p>България 
Ю СИ БИ България ЕООД 
Teл.: + 359 (0) 2 962 30 Luxembourg/Luxemburg 
UCB Pharma SA/NV 
Tél/Tel: + 32 / (0)2 559 92 00 (Belgique/Belgien) </p>
<p>Česká republika 
UCB s.r.o. 
Tel: + 420 221 773<br />
Magyarország 
UCB Magyarország Kft. 
Tel.: + 36-(1) 391 0 
Danmark 
UCB Nordic A/S 
Tlf: + 45 / 32 46 24<br />
Malta 
Pharmasud Ltd. 
Tel: + 356 / 21 37 64<br />
Deutschland 
UCB Pharma GmbH 
Tel: + 49 /(0) 2173 48 4 
Nederland 
UCB Pharma B.V. 
Tel.: + 31 / (0)76-573 11<br />
Eesti 
UCB Pharma Oy Finland<br />
Tel: + 358 9 2514 4221 (Soome) </p>
<p>Norge 
UCB Nordic A/S 
Tlf: + 47 / 67 16 5 
Ελλάδα 
UCB Α.Ε.<br />
Τηλ: + 30 / 2109974 
Österreich 
UCB Pharma GmbH 
Tel: + 43-(0)1 291 80 España 
UCB Pharma, S.A. 
Tel: + 34 / 91 570 34<br />
Polska 
UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. 
Tel: + 48 22 696 99<br />
France 
UCB Pharma S.A. 
Tél: + 33 / (0)1 47 29 44 Portugal 
UCB Pharma (Produtos Farmacêuticos), Lda 
Tel: + 351 / 21 302 5 
Hrvatska 
Medis Adria d.o.o. 
Tel: +385 (0) 1 230 34<br />
România 
UCB Pharma Romania S.R.L. 
Tel: + 40 21 300 29<br />
Ireland 
UCB (Pharma) Ireland Ltd. 
Tel: + 353 / (0)1-46 37 395  </p>
<p>Slovenija 
Medis, d.o.o. 
Tel: + 386 1 589 69<br />
Ísland 
Vistor hf. 
Simi: + 354 535 7 
Slovenská republika 
UCB s.r.o., organizačná zložka 
Tel: + 421 (0) 2 5920 2 
Italia 
UCB Pharma S.p.A. 
Tel: + 39 / 02 300 Suomi/Finland 
UCB Pharma Oy Finland 
Puh/Tel: + 358 9 2514 4 
Κύπρος 
Lifepharma (Z.A.M.) Ltd 
Τηλ: + 357 22 05 63 00  </p>
<p>Sverige 
UCB Nordic A/S 
Tel: + 46 / (0) 40 29 49 Latvija 
UCB Pharma Oy Finland 
Tel: + 358 9 2514 4221 (Somija) </p>
<p>United Kingdom (Northern Ireland) 
UCB (Pharma) Ireland Ltd. 
Tel: + 353 / (0)1-46 37<br />
Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}. </p>
<p>Yderligere oplysninger 
De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu.  </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Briviact 10 mg/ml oral opløsning 
brivaracetam </p>
<p>Læs denne indlægsseddel grundigt, inden De begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. De kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, De vil vide. 
- Lægen har ordineret dette lægemiddel til Dem personligt. Lad derfor være med at give 
medicinen til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som 
De har. 
- Kontakt lægen eller apotekspersonalet, hvis De får bivirkninger, herunder bivirkninger, som 
ikke er nævnt her. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-67d662579a878d3df2de1273192e0a02
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for briviact Package Leaflet for language en"
Description: "ePI document Bundle for briviact Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-67d662579a878d3df2de1273192e0a02"
* entry[0].resource = composition-en-67d662579a878d3df2de1273192e0a02

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp67d662579a878d3df2de1273192e0a02"
* entry[=].resource = mp67d662579a878d3df2de1273192e0a02
                            
                    
Instance: bundlepackageleaflet-da-67d662579a878d3df2de1273192e0a02
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for briviact Package Leaflet for language da"
Description: "ePI document Bundle for briviact Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-67d662579a878d3df2de1273192e0a02"
* entry[0].resource = composition-da-67d662579a878d3df2de1273192e0a02

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp67d662579a878d3df2de1273192e0a02"
* entry[=].resource = mp67d662579a878d3df2de1273192e0a02
                            
                    



Instance: mp67d662579a878d3df2de1273192e0a02
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Briviact 10 mg film-coated tablets"
Description: "Briviact 10 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/1073/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Briviact 10 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 67d662579a878d3df2de1273192e0a02ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "briviact"

* status = #current
* mode = #working

* title = "List of all ePIs associated with briviact"

* subject = Reference(mp67d662579a878d3df2de1273192e0a02)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#briviact "briviact"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-67d662579a878d3df2de1273192e0a02) // briviact en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-67d662579a878d3df2de1273192e0a02) // briviact da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-67d662579a878d3df2de1273192e0a02
InstanceOf: List

* insert 67d662579a878d3df2de1273192e0a02ListRuleset
    